Chloroquine, Efficacy, Malaria, Vivax Malaria
Conditions
Keywords
Therapeutic, Efficacy, Chloroquine, Primaquine, Ethiopia
Brief summary
The goal of this open label clinical trial will be to assess the therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia. The main question it aims to answer:- the current therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia based on clinical, parasitological and hematological parameter. Participants will be patients aged \>6 months with diagnosis of plasmodium vivax mono-infection and who fulfills the inclusion criteria. This is a single arm open label invivo therapeutic efficacy study of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax. The final result will be compared with World Health Organization recommendation on antimalarial drug therapeutic efficacy.
Detailed description
The goal of this open label clinical trial will be to assess the therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia. The main question it aims to answer:- the current therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia based on clinical, parasitological and hematological parameter. Participants will be patients aged \>6 months with diagnosis of plasmodium vivax mono-infection and who fulfills the inclusion criteria. This is a single arm open label invivo therapeutic efficacy study of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax. The final result will be compared with World Health Organization recommendation on antimalarial drug therapeutic efficacy.
Interventions
DRUGChloroquine
Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
DRUGPrimaquine
Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
Sponsors
Ethiopian Public Health Institute
Dinka Dugassa
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open label clinical trial study will be conducted in Shecha Health Center from December 2022 to March 2023. Participants will be selected and treated with a 25 mg/kg standard dose of chloroquine over three days and a 0.25 mg/kg standard dose of primaquine over fourteen days. Clinical, parasitologic, and hematologic parameters will be monitored for up to a 42-day follow-up period, which will be used to evaluate therapeutic efficacy of CQ+PQ. Thick and thin blood smears will be prepared and examined to determine parasite clearance, and clinical examination will be performed over 42 follow up periods. Haemoglobin level will be measured on days 0, 14, 28 and 42. WHO double-entry Excel sheet will be used for KaplanMeier survival analysis and SPSS version-26 software will be used to analyse the data. All comparisons will be performed at 95% confidence interval and a significance level of 0.05, Pvalue of \<0.05 will be considered statistically significant
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 6 months * Slide confirmed infection with P. vivax with \> 250 asexual forms/μl * Lives within 5 km of the enrolling health facility * Weight ≥ 5.0 kg * Ability to swallow oral medication * Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule * Informed consent from patient or from a parent or guardian in the case of children
Exclusion criteria
* Sever malaria with complication sign and symptoms * Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean, symmetrical edema involving at least the feet, or mid-upper arm circumference \<100 cm for children less than five years of age * Mixed plasmodium infection * Severe anemia, defined as hemoglobin (Hb) \< 5 g/dl * Presence of febrile conditions caused by diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) * Serious or chronic medical condition (e.g. cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS) * Positive pregnancy test or breastfeeding * Unable or unwilling to take contraceptives for women of child-bearing age * Children weighing less than 5 kilograms * History of hypersensitivity reaction to any medication tested or used as an alternative treatment * Participants with history of prolonged QT conditions * Taking regular medication, which may interfere with antimalarial pharmacokinetics or efficacy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early treatment failure [Time Frame: within the first 3 days] | within the first 3 days | Danger signs or severe malaria on day 1, day 2 or day 3 in the presence of parasitemia;Parasitemia on day 2 higher than on day 0, irrespective of axillary temperature;Parasitemia on day 3 with axillary temperature ≥37.5 ºC;Parasitemia on day 3 ≥25% of count on day 0. |
| Late Clinical Failure (LCF) | 42 days | Danger signs or severe malaria in the presence of parasitemia on any day between day 4 and 42 in patients who did not previously meet any of the criteria of Early Treatment Failure; Presence of parasitemia on any day between 4 and day 42 with axillary temperature ≥37.5 °C (or history of fever) in patients who did not previously meet any of the criteria of Early Treatment Failure. |
| Late Parasitological Failure (LPF) | 42 days | Presence of parasitemia on any day between day 7 and day 42 and axillary temperature \<37.5 ºC in patients who did not previous meeting any of the criteria of Early Treatment Failure or Late Clinical Failure. |
| Adequate Clinical and Parasitological Response (ACPR) | 42 days | Absence of parasitemia on day 42 irrespective of axillary temperature, in patients who did not previously meet any of the criteria of Early Treatment Failure, Late Clinical Failure, or Late Parasitological Failure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The secondary outcome of this study is determining parasite clearance rate based on parasite clearance time. | 42 days | This study's secondary goal was to calculate the parasite clearance rate based on parasite clearance time. Using hours, days, weeks, and months, parasite clearance time is calculated. |
| The secondary outcome of this study is evaluating the incidence of adverse events in 42 follow-up period. | 42 days | This study's secondary goal was evaluating the incidence of adverse events in 42 follow-up period. |
| The secondary outcome of this study is determining gametocyte clearance rate based on gametocyte clearance time. | 42 days | This study's secondary goal was to calculate the gametocyte clearance rate based on gametocyte clearance time. Using hours, days, weeks, and months, parasite clearance time is calculated. |
| The secondary outcome of this study is determining fever clearance rate based on fever clearance time. | 42 days | Calculating the fever clearance rate based on fever clearance time was the secondary outcome of this clinical trial. Fever clearance time is calculated using hours, days, weeks, and months. Temperatures less than 37.5 degrees celsius (T 37.5oC) are deemed to be fever-free(fever cleared) while temperatures greater than or equal to 37.5 degrees celsius (T\>37.5oC) are classified as having fever (fever not cleared). |
| The secondary outcome of this study is determining mean hemoglobin change overtime in the 42 days study period. | 42 days | Calculating the mean hemoglobin change overtime in the 42 study period based on hemoglobin concentration at D0, D14, D28 and D42 was the secondary outcome of this clinical trial. Milligrammes per deciliter are used to measure the concentration of haemoglobin. |
Countries
Ethiopia
Outcome results
None listed